BAMCO Inc’s Cytokinetics CYTK Stock Holding History

BAMCO Inc’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$852K	Sell	10,000 -13,000	-57%	-$933K	﹤0.01%	301
2026 Q1	$1.52M	Buy	+23,000	New	+$1.46M	﹤0.01%	285
2025 Q4	–	Sell	-24,500	Closed	-$1.35M	–	336
2025 Q3	$1.35M	Buy	+24,500	New	+$1.01M	﹤0.01%	293
2023 Q4	–	Sell	-25,000	Closed	-$737K	–	335
2023 Q3	$737K	Sell	25,000 -15,000	-38%	-$500K	﹤0.01%	304
2023 Q2	$1.3M	Sell	40,000 -8,100	-17%	-$300K	﹤0.01%	305
2023 Q1	$1.69M	Buy	48,100 +4,000	+9%	+$163K	0.01%	304
2022 Q4	$2.02M	Buy	44,100 +16,100	+58%	+$693K	0.01%	312
2022 Q3	$1.36M	Hold	28,000	–	–	﹤0.01%	321
2022 Q2	$1.1M	Sell	28,000 -10,000	-26%	-$403K	﹤0.01%	336
2022 Q1	$1.4M	Sell	38,000 -10,000	-21%	-$355K	﹤0.01%	347
2021 Q4	$2.19M	Buy	+48,000	New	+$1.85M	﹤0.01%	348

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc's CYTK Position: Q2 2026 in Review

BAMCO Inc reduced its Cytokinetics (CYTK) stake by 57% in Q2 2026, selling an estimated $933K and leaving 10,000 shares worth $852K. The position accounts for ﹤0.01% of the portfolio, ranked #301.

BAMCO Inc first reported a position in CYTK in Q4 2021 and has held it in 11 quarters since. The position peaked at $2.19M in Q4 2021. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

BAMCO Inc held 10,000 shares of Cytokinetics worth $852K as of Q2 2026.
BAMCO Inc sold 13,000 Cytokinetics shares in Q2 2026, an estimated $933K.
Cytokinetics made up ﹤0.01% of BAMCO Inc's portfolio in Q2 2026, its #301 holding.
BAMCO Inc first reported a position in Cytokinetics in Q4 2021 and has held it in 11 quarters since.
BAMCO Inc's Cytokinetics position peaked at $2.19M in Q4 2021.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on BAMCO Inc's 13F filing for Q2 2026, filed 14 Aug 2026.